Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (2603)	1/8/2011 12:03:45 AM
From: richardred	Respond to of 7242

Hologic to Acquire Interlace Medical for $125M By Jennifer Booton Published January 07, 2011 Medical device maker Hologic (HOLX) has agreed to buy privately-held Interlace Medical for $125 million in an effort to strengthen its position as a leader in women’s health care. Based in Bedford, Mass, Hologic, which manufactures and supplies premium diagnostics, medical imaging systems and surgical products dedicated to the health-care needs of women, said Interlace will be integrated within its GYN Surgical Products division. Interlace, based in Framingham, Mass, makes the MyoSure hysteroscopic tissue removal system and is dedicated to developing innovative technologies to treat common gynecological disease for improved patient outcomes. It also seeks to simplify physicians’ adoption and reduce healthcare costs. MyoSure is designed to safely and easily remove fibroids and polyps from women, providing women with minimally-invasive treatment options, the companies said. "The acquisition of Interlace is consistent with our strategy to strengthen our leadership position in women's healthcare," said Steve Williamson, senior vice president and general manager of GYN Surgical Products. The $125 million purchase price is subject to adjustment, plus two annual contingent payments, which will be payable in cash and each calculated as a multiple of the incremental revenue growth over the prior year. Read more: foxbusiness.com

To: richardred who wrote (2603)	11/17/2013 12:58:16 PM
From: richardred	Respond to of 7242

2013 Medtech M&A Review: Conclusion and 2014 Outlook Posted in Medical Device Business by MDDI Staff on November 15, 2013 Don't expect medtech M&A's to slow in 2014. By Clyde A. Burkhardt It’s likely that 2014 will also be a very active year for medical device and diagnostic mergers and acquisitions. The year may start off with a very large blockbuster transaction if Johnson & Johnson reaches an agreement to sell its diagnostics unit, which is focused on blood screening equipment and laboratory blood tests. Reportedly, a full-blown auction process is underway and a consortium of Danaher Corp. and Blackstone, one of the largest U.S. private equity funds, is competing against several other private equity funds. The price is reportedly in the range of $4 billion. Many of the large potential buyers in medtech continue to have strategic growth plans that include making acquisitions to enhance their existing product portfolios with new products, and to diversify into medtech segments with good long-term growth prospects. Private equity investors have an estimated $500 billion in capital for acquisitions and many are very interested in acquiring medtech companies to use as platforms to build large companies organically and through additional acquisitions. Several private equity funds sold their medtech companies in 2013, and there will likely be additional private equity exits in 2014. Some of the private equity medtech exits over the past two years provided excellent returns for the investors, and that has attracted the attention and sparked the interest of other private equity funds. Next year is also likely to bring additional divestiture activity, as some of the larger medtech companies continue to shed noncore or underperforming operations and redeploy the sale proceeds to grow their core businesses with the best growth potential or diversify by acquiring companies with favorable growth prospects. As some of the transactions discussed illustrate, many medtech buyers are interested in acquiring companies with leading-edge, next-generation products and therapies. A window of opportunity will remain open in 2014 for the owners of such companies to sell their businesses at attractive prices. While the medtech industry in general faces many problems and challenges, including the Affordable Care Act, the mergers acquisition climate was healthy in 2013 and will likely remain healthy for most medtech segments in 2014. mddionline.com